FOR IMMEDIATE RELEASE
Ashley L. Kierkiewicz
firstname.lastname@example.org • (808) 989-4004
JENKINS EYE CARE SURGEONS FIRST IN HONOLULU TO IMPLANT iSTENT INJECT
Procedure Addresses Cataracts and Glaucoma at the Same Time
[HONOLULU, HI – OCTOBER 16, 2018]— Ophthalmological surgeons Jeffrey Peterson, M.D., Ph.D., and Tyrie Jenkins, M.D., of Jenkins Eye Care were the first in Honolulu to implant iStent inject®, which safely lowers intraocular pressure and improves the eye’s natural ability to drain fluid.
The device is implanted during cataract surgery, creating an opportunity to treat glaucoma in patients undergoing cataract surgery.
Approved by the U.S. Food & Drug Administration in June 2018, the iStent inject® involves inserting two tiny surgical-grade titanium implants that create bypasses, or openings, that restore the eye’s natural ability to drain fluid.
The iStent inject®is the world’s smallest medical device known to be implanted in the human body. Once inserted, the patient will not be able to see or feel the device. It is the latest innovation in trabecular micro-bypass devices, which have been implanted in hundreds of thousands of eyes all around the world.
“This is a compelling option for cataract patients in our community that are living with glaucoma,” said Dr. Peterson. “Glaucoma is a vision-threatening condition that can lead to blindness if left untreated. The iStent inject® is an advanced option that can assist in the management of eye pressure associated with glaucoma, and may also reduce patient’s reliance on glaucoma medications.”
“Adding iStent inject®to our suite of offerings was an easy decision for us,” said Dr. Jenkins. “We believe this technology will benefit the patients in our community living with both cataracts and glaucoma.”
Developed by Glaukos, an ophthalmic medical technology and pharmaceutical company, the iStent inject®is the next-generation of the company’s pioneering iStent. In April 2013, Jenkins Eye Care was first in Hawaii to offer the first generation iStent.
For more information on iStent inject, contact Jenkins Eye Care at (808) 591-9911 or online at www.jenkinseyecare.com.
ABOUT iStent inject
iStent inject® is indicated for use in conjunction with cataract surgery for adult patients with mild to moderate primary open-angle glaucoma. Once implanted in the eye, iStent injectcan effectively lower intraocular pressure and patients may experience a reduction in reliance on glaucoma medication (at discretion of eye care professional).
Glaucoma is a group of diseases that damage the eye’s optic nerve and can result in vision loss and blindness. Several large studies have shown that eye pressure is a major risk factor for optic nerve damage. In open-angle glaucoma, even though an ocular fluid drainage angle is open, the fluid passes too slowly through a meshwork drain. When the fluid builds up, the pressure inside the eye rises to a level that may damage the optic nerve. When the optic nerve is damaged from increased pressure, open-angle glaucoma-and vision loss may result. In 20010, 60.5 million people globally were living with glaucoma. Given the world’s aging population, the number of people living with glaucoma may increase to nearly 80 million by 2020.